SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently in the spotlight as investors weigh its pivot toward the high-growth AI infrastructure market against mixed financial performance. The community is heavily focused on the company's reinstated bookings guidance and reports of significant capacity interest from major hyperscalers, leading to a polarized debate between long-term bullish sentiment and concerns over near-term revenue volatility.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is generating buzz as investors weigh the strategic implications of its controlling shareholder's acquisition of Blue Bottle Coffee against ongoing speculation regarding a potential U.S. relisting. While some community members express frustration over low trading volume and price volatility, others argue that the company's aggressive expansion and dominant position in the Chinese market present a deep-value opportunity for patient holders.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending as investors focus on the upcoming earnings report and expectations for fiscal 2027 guidance and royalty backlog updates. The community remains highly polarized, with intense debate between long-term "believers" who highlight QNX's role in the software-defined vehicle market and skeptics who express frustration over stagnant stock performance and past revenue trends.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending after receiving FDA approval for VYKAT XR, the first and only treatment for hyperphagia in Prader-Willi syndrome, triggering a major rally and intense community speculation regarding potential buyout interest. Investors are closely monitoring the commercial launch strategy and the company's valuation, as many compare the setup to previous rare disease success stories while discussing the stock's long-term momentum.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors react to a second round of subscription price increases across all tiers, a move aimed at boosting margins and funding a massive content budget. The stock is exhibiting notable relative strength, with community members actively discussing a potential breakout toward the 100 level and debating whether this pricing power effectively offsets broader streaming sector headwinds.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is facing intense selling pressure and high volatility following a recent reverse stock split, with retail investors increasingly frustrated by management's silence and the lack of guidance. The community is deeply divided between those betting on an epic short squeeze due to the low float and those who are cutting losses, warning of further downside as the stock struggles to find a floor.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently a major focus for investors as it balances a record-breaking revenue quarter and a significant share repurchase program against continued skepticism regarding production scaling and testing delays. While the community remains sharply divided, sentiment is currently driven by discussions around the potential for an upcoming purchase order for its high-energy-density batteries and the technical challenges the company faces in reaching mass production.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology (STX) is trending as institutional analysts aggressively upgrade price targets, citing a structural expansion in the hard disk drive cycle and sustained hyperscaler demand. While the stock has seen significant volatility, community discussion remains divided between those betting on long-term data center supply shortages through 2028 and others cautioning against an overheated memory sector.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant community buzz driven by its low circulating supply and market cap, which proponents believe positions the token for a massive supply shock if volume spikes. While some investors express skepticism regarding its historical performance and lack of adoption, others are actively accumulating in anticipation of a potential breakout fueled by its DeFi and NFT platform integration.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a major focus of community debate as investors weigh significant price volatility against potential institutional catalysts, including recent reports of enterprise adoption and anticipation surrounding the Clarity Act. While some retail traders are aggressively averaging down at multi-year lows, others remain deeply frustrated by the lack of sustained momentum and the asset's historical underperformance relative to other major tokens.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

Equity

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>The German drugmaker will transfer select intellectual property to the new entity while retaining a minority stake.</li><li>The new entity will operate independently with its own financial structure, research agenda, and operational framework.</li><li>BioNTech will continue concentrating on its expanding late-stage development portfolio.</li></ul>BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing next-generation messenger RNA technologies, with the initiative to be led by its co-founders Ugur Sahin and Prof. Özlem Türeci, who are set to leave the company to head the new venture.&nbsp;&nbsp;The new entity will operate independently with its own financial structure, research agenda, and operational framework while collaborating with BioNTech in specific areas of development.Following the announcement, BioNTech stock tumbled nearly 17% in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h3>Founders Exit To Lead New mRNA Venture</h3>The Germany-based company intends to transfer certain intellectual property and technology assets tied to mRNA research to the new organization while retaining a minority ownership stake and potential milestone or royalty payments.The forthcoming company will concentrate exclusively on developing emerging mRNA platform technologies with potential medical applications.<h3>BioNTech Keeps Focus On Oncology Pipeline</h3>While the new venture focuses on experimental mRNA innovation, BioNTech will continue concentrating on its expanding late-stage development portfolio. The company expects around 15 Phase 3 clinical trials in oncology to be underway by the end of 2026.&nbsp;“We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients”.-Helmut Jeggle, Chairman, BioNTech Supervisory Board<h2 class="st-heading-2">Q4 Earnings Pressure&nbsp;</h2>BioNTech reported a 23% year-on-year (YoY) decline in fourth-quarter earnings to €907.4 million ($1.05 billion). Loss per share also widened to €1.25 from a loss per share of €0.33 last year.&nbsp;BNTX stock has declined by 3% in the last 12 months.&nbsp;Conversion Rate: €1=$1.16Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/att-250-billion-fiber-5g-network-investment-plan/cZdoY58RIew">AT&amp;T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech mRNA-based vaccine manufacturing site in Rwanda | Source: BioNTech

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  

<ul class="summary-bullets"><li>Moderna has submitted a revised approach to streamline approval based on age-specific indications.</li><li>The company proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults 65 and older.</li><li>Last week, the FDA refused to review Moderna’s application for the flu vaccine.</li></ul>Moderna, Inc. (MRNA) said on Wednesday that it is moving forward with regulatory review for its investigational seasonal flu vaccine, mRNA-1010, after responding to a prior Refusal-to-File letter from the U.S. Food and Drug Administration (FDA).&nbsp;The company has submitted a revised approach to streamline approvals based on age-specific indications.<h2 class="st-heading-2">Targeted Approval Strategy</h2>Moderna proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, along with a post-marketing study to further evaluate safety and efficacy in older populations.The FDA has now accepted the biologics license application (BLA) for review, setting a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026.<blockquote>"Pending FDA approval, we look forward to making our flu vaccine available later this year so that America's seniors have access to a new option to protect themselves against flu."-Stéphane Bancel, CEO, Moderna</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> traded over 5% higher on Wednesday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_091941_png_316eca4dee.webp" alt="MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global Regulatory Progress</h2>mRNA-1010 has entered regulatory review not only in the U.S. but also in Europe, Canada, and Australia, with additional filings planned for later in 2026. Moderna anticipates the first potential approvals for the vaccine to occur within the year.If approved, mRNA-1010 would be available for U.S. adults aged 50 and above, including those 65 and older, for the 2026/2027 influenza season.&nbsp;Last week, the FDA refused to review Moderna’s application for the flu vaccine and cited the lack of an "adequate and well-controlled" study with a comparator arm that "does not reflect the best-available standard of care."&nbsp;MRNA stock has gained over 28% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/walmart-earnings-can-wmt-stock-sustain-momentum-under-new-ceo/cZR0ZxRR4Hs">Walmart Earnings Ahead: Can WMT Stock Sustain Momentum Under New CEO?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

Current Price	$44.30
Prev Close	$44.19
Open	$44.30
Dividend Yield	N/A
50-Day Moving Average	$45.79
Beta	N/A
Avg. Volume	11,910.92
PE Ratio	N/A

52-Week High	$51.42
52-Week Low	$27.20
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

GNOM
Global X Funds - Global X Genomics & Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GNOM News

GNOMGlobal X Funds - Global X Genomics & Biotechnology ETF